Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2024 08:00 ET | Source: Numab Therapeutics AG

Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors

NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular...
September 05, 2023 07:00 ET | Source: Engitix Therapeutics

Engitix Announces Appointment of Christopher Stevenson, Ph.D., as Chief Scientific Officer

LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary...
May 09, 2023 04:00 ET | Source: Engitix Therapeutics

Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director

LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
June 03, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has initiated a new...